Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-16673 in Relapsed/Refractory B-cell Malignancies (WM Cohort)
CTR20254960Phase 2Active
- Sponsor
- BeiGene
- Start
- Jan 2026
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of catadegbrutinib in mature B-cell lymphoma, Waldenström macroglobulinemia (WM), B-cell malignancy, sponsored by BeiGene. Started Jan 2026; status: active.
02
Drugs
catadegbrutinib
03
Conditions
mature B-cell lymphomaWaldenström macroglobulinemia (WM)B-cell malignancy
Beyond the preview
Go deeper on CTR20254960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254960.